Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06757634 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
A Phase 3 study of Breast Cancer, sponsored by Celcuity.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 674
- Enrollment target
- 20
- Study locations
NCT06757634 is a Phase 3 study of Breast Cancer that is actively recruiting participants, run by Celcuity. The registered enrollment target is 674 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT06757634, a Phase 3 study of Breast Cancer, is actively recruiting participants, sponsored by Celcuity.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 674 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant and CDK4/6 Inhibitors for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.
Conditions Studied
Interventions
- DRUG Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant
- DRUG Arm B: Palbociclib or Ribociclib + Fulvestrant
Study Locations (20)
California
- City of Hope Medical Center - Duarte
- Providence Medical Foundation - Fullerton
- UCLA Hematology Oncology Santa Monica - Los Angeles
Florida
- BRCR Medical Center, Inc- Internal Medicine - Plantation
- BRCR Medical Center, INC - Tamarac
Missouri
- Saint Luke's Cancer Institute - Kansas City
- Washington University School of Medicine in Saint Louis - St Louis
New York
- Weill Cornell Medical College - NewYork-Presbyterian Hospital - New York
- Clinical Research Alliance, Inc. - Westbury
Texas
- University of Texas MD Anderson Cancer Center - Houston
- Mays Cancer Center - San Antonio
Kansas
- The University of Kansas Cancer Center - Westwood
Kentucky
- Mercy Health-Paducah Cancer Center - Paducah
Maryland
- American Oncology Partners, P.A. - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 674 participants |
| Start Date | 2025-07-24 |
| Est. Completion | 2028-12-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06757634
The ClinicalTrials.gov registry entry for NCT06757634 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 674 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (76% lower). The listed sponsor is Celcuity, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant is the first listed.
NCT06757634 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT06757634 about?
NCT06757634 is a clinical study titled "Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)". This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant and CDK4/6 Inhibitors for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.
What is the current status of trial NCT06757634?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 674 participants. The study started on 2025-07-24. Estimated completion is 2028-12-30.
What conditions does trial NCT06757634 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT06757634?
The interventions under investigation include: Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant (DRUG), Arm B: Palbociclib or Ribociclib + Fulvestrant (DRUG).
Who is sponsoring clinical trial NCT06757634?
This trial is sponsored by Celcuity, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06757634 being conducted?
This trial has 20 study locations across California, Florida, Kansas, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.